These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 26094276)

  • 1. Many in VOICE trial didn't use provided prevention products.
    AIDS Policy Law; 2015 Mar; 30(4):3. PubMed ID: 26094276
    [No Abstract]   [Full Text] [Related]  

  • 2. Unethical clinical trials in Thailand: a community response.
    Loff B; Jenkins C; Ditmore M; Overs C; Barbero R
    Lancet; 2005 May 7-13; 365(9471):1618-9. PubMed ID: 15889464
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
    Karim SS; Kashuba AD; Werner L; Karim QA
    Lancet; 2011 Jul; 378(9787):279-81. PubMed ID: 21763939
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral tenofovir arm of VOICE trial discontinued early.
    McEnery R
    IAVI Rep; 2011; 15(5):21. PubMed ID: 22121550
    [No Abstract]   [Full Text] [Related]  

  • 5. Female-initiated prevention strategies key to tackling HIV.
    Nelson R
    Lancet Infect Dis; 2007 Oct; 7(10):637. PubMed ID: 17939181
    [No Abstract]   [Full Text] [Related]  

  • 6. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiretrovirals for HIV prevention: translating promise into praxis.
    Mayer KH
    Lancet; 2011 Jul; 378(9787):206-8. PubMed ID: 21763922
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicines Control Council and registration backlog of antiretrovirals.
    Gosling J
    S Afr Med J; 2007 Apr; 97(4):232. PubMed ID: 17446940
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiretroviral vaginal gel shows promise against HIV.
    Baleta A
    Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
    [No Abstract]   [Full Text] [Related]  

  • 10. The trials of tenofovir trials.
    Lancet; 2005 Mar 26-Apr 1; 365(9465):1111. PubMed ID: 15799093
    [No Abstract]   [Full Text] [Related]  

  • 11. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 12. We must not let protestors derail trials of pre-exposure prophylaxis for HIV.
    Lange JM
    PLoS Med; 2005 Sep; 2(9):e248. PubMed ID: 16008501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong?
    Singh JA; Mills EJ
    PLoS Med; 2005 Sep; 2(9):e234. PubMed ID: 16008507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
    Rahman SM; Vaidya NK; Zou X
    J Theor Biol; 2014 Apr; 347():151-9. PubMed ID: 24380779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registration problems for antiretrovirals in Africa.
    Ford N; Darder M
    Lancet; 2006 Mar; 367(9513):794-5. PubMed ID: 16530559
    [No Abstract]   [Full Text] [Related]  

  • 16. After CAPRISA 004: time to re-evaluate the HIV lexicon.
    Cates W
    Lancet; 2010 Aug; 376(9740):495-6. PubMed ID: 20709216
    [No Abstract]   [Full Text] [Related]  

  • 17. Unethical clinical trials in Thailand: a community response.
    Jintarkanon S; Nakapiew S; Tienudom N; Suwannawong P; Wilson D
    Lancet; 2005 May 7-13; 365(9471):1617-8. PubMed ID: 15885287
    [No Abstract]   [Full Text] [Related]  

  • 18. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 19. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 20. [The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
    MMW Fortschr Med; 2003 Jun; 145(24):52. PubMed ID: 12866303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.